New phase 3 results should reopen discussion about the off-label use of COMT inhibitors in early Parkinson's disease, experts ...

An experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson's significantly reduce ...

Amneal is releasing Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease.

Discover Amneal Pharmaceuticals' innovative patent for a controlled release levodopa formulation, enhancing drug delivery without decarboxylase inhibitors.

Semaglutide, the same compound that’s in Ozempic, is part of a class of medications known as glucagon-like peptide 1 (GLP-1) ...

The results of these findings were recently published in Molecular Psychiatry. Treatment of Parkinson's disease is in large part based on the administration of levodopa. The use of this drug is ...

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has launched CREXONT ® (carbidopa and levodopa) extended-release capsules for the treatment ...

27 – Oct. 1, 2024 Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has launched CREXONT® (carbidopa ...

Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously ...

The voluminous papers of the celebrated neurologist include letters, notebooks, drafts and other traces of a man who couldn’t ...

A question and answer session with Prof Suzanne Timmons, Professor of Geriatric Medicine at University College Cork ...